We investigated the effects of transdermal 17 beta-estradiol, combined with standard antihypertensive therapy, on the modification of the cardiovascular risk profile in hypertensive postmenopausal women. In a randomized, double-blind, placebo-controlled study, we enrolled 200 postmenopausal women with mild to moderate hypertension. Patients received 17 beta-estradiol (50 mu g/day, transdermal) and norethisterone acetate (2.5 mg/day, orally) or placebo. At baseline serum total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, glucose, and fibrinogen plasma levels were measured and all subjects underwent complete M-mode and 2-D echocardiograms, which were repeated after 6, 12 and 18 months of hormonal replacement therapy. Compared with. placebo, all values decreased significantly except for HDL cholesterol. In both groups, no modifications were observed in echocardiographic parameters, except for left ventricular mean diastolic and systolic wall thickness and left ventricular mass index, which showed a significant decrease in both groups. The reduction was greater in the treated group; the percentage of patients with left ventricular hypertrophy was 46% before randomization and 17.2% after 18 months of treatment (P < .0001), whereas in group II the percentage was 48% at baseline and 31.5% after 18 months (P < .05). In conclusion transdermal 17 beta-estradiol, associated with antihypertensive therapy,may contribute to the reduction of cardiovascular risk profile in hypertensive postmenopausal women.

Double-blind randomized placebo-controlled study of transdermal estrogen replacement therapy on hypertensive postmenopausal women / Modena, Maria Grazia; R., Molinari; N., Muia; A., Castelli; F., Pala; Rossi, Rosario. - In: AMERICAN JOURNAL OF HYPERTENSION. - ISSN 0895-7061. - STAMPA. - 12:(1999), pp. 1000-1008.

Double-blind randomized placebo-controlled study of transdermal estrogen replacement therapy on hypertensive postmenopausal women

MODENA, Maria Grazia;ROSSI, Rosario
1999

Abstract

We investigated the effects of transdermal 17 beta-estradiol, combined with standard antihypertensive therapy, on the modification of the cardiovascular risk profile in hypertensive postmenopausal women. In a randomized, double-blind, placebo-controlled study, we enrolled 200 postmenopausal women with mild to moderate hypertension. Patients received 17 beta-estradiol (50 mu g/day, transdermal) and norethisterone acetate (2.5 mg/day, orally) or placebo. At baseline serum total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, glucose, and fibrinogen plasma levels were measured and all subjects underwent complete M-mode and 2-D echocardiograms, which were repeated after 6, 12 and 18 months of hormonal replacement therapy. Compared with. placebo, all values decreased significantly except for HDL cholesterol. In both groups, no modifications were observed in echocardiographic parameters, except for left ventricular mean diastolic and systolic wall thickness and left ventricular mass index, which showed a significant decrease in both groups. The reduction was greater in the treated group; the percentage of patients with left ventricular hypertrophy was 46% before randomization and 17.2% after 18 months of treatment (P < .0001), whereas in group II the percentage was 48% at baseline and 31.5% after 18 months (P < .05). In conclusion transdermal 17 beta-estradiol, associated with antihypertensive therapy,may contribute to the reduction of cardiovascular risk profile in hypertensive postmenopausal women.
12
1000
1008
Double-blind randomized placebo-controlled study of transdermal estrogen replacement therapy on hypertensive postmenopausal women / Modena, Maria Grazia; R., Molinari; N., Muia; A., Castelli; F., Pala; Rossi, Rosario. - In: AMERICAN JOURNAL OF HYPERTENSION. - ISSN 0895-7061. - STAMPA. - 12:(1999), pp. 1000-1008.
Modena, Maria Grazia; R., Molinari; N., Muia; A., Castelli; F., Pala; Rossi, Rosario
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/306049
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 48
  • ???jsp.display-item.citation.isi??? 41
social impact